Biomarker discovery for colon cancer using a 761 gene RT-PCR assay.

ABSTRACT:

Background

Reverse transcription PCR (RT-PCR) is widely recognized to be the gold standard method for quantifying gene expression. Studies using RT-PCR technology as a discovery tool have historically been limited to relatively small gene sets compared to other gene expression platforms such as microarrays. We have recently shown that TaqMan RT-PCR can be scaled up to profile expression for 192 genes in fixed paraffin-embedded (FPE) clinical study tumor specimens. This technology has also been used to develop and commercialize a widely used clinical test for breast cancer prognosis and prediction, the Onco typeDX assay. A similar need exists in colon cancer for a test that provides information on the likelihood of disease recurrence in colon cancer (prognosis) and the likelihood of

SUBMITTER: Clark-Langone KM 

PROVIDER: S-EPMC1994687 | biostudies-literature | 2007 Aug

REPOSITORIES: biostudies-literature